Annual review of The Branded Health Service Medicines (Costs) Regulations 2018

This review considers the extent to which the 2018 regulations have achieved their objectives, which are: to limit the growth in costs of branded health service medicines to safeguard the financial position of the NHS; to ensure medicines are available on reasonable terms, accounting for the costs of research and development; and to deliver the above objectives in a way consistent with supporting both the life sciences sector and broader economy.

Source: NHS Networks - April 3, 2019 Category: UK Health Source Type: news